Clinical Trial

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-09-24; most recent amendment 2025-09-10.
Status change: Not Yet Recruiting → Recruiting 2022-12-14
Trial Details
NCT Number NCT04105270
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Adenocarcinoma of Lung, Lung Cancer
Enrollment 82 participants
Start Date 2022-11-30
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-11